Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
The original release is unavailable here.
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- ACW accesses up to $13.8m in non-dilutive R&D tax funding
- ACW 100th AD trial participant & interim analysis timeline
- Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news
- Actinogen March 2025 quarterly activity report & Appendix 4C
- ACW conducts Type C meeting with FDA regarding depression
Later from Actinogen Medical
- A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US
- Actinogen June 2025 quarterly activity report & Appendix 4C
- ACW Appendix 4E and 2025 annual report
- ACW FY2025 results - accelerating Alzheimers pivotal trial
- ACW pharmacokinetics trial success
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical